Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
about
Overview and recent advances in the treatment of neuroblastoma.Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomesTumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma.Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltrationGenetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.Advances in Risk Classification and Treatment Strategies for Neuroblastoma.Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors.Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis?Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectPrognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastomaIntra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications.Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial.Ten challenges in the management of neuroblastoma.Children's Oncology Group's 2013 blueprint for research: neuroblastoma.New prognostic markers in neuroblastoma.Recent insights into the biology of neuroblastoma.Genetic discoveries and treatment advances in neuroblastoma.Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.Comprehensive cytogenomic profile of the in vitro neuronal model SH-SY5Y.Bone marrows from neuroblastoma patients: an excellent source for tumor genome analysesRadiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression.Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
P2860
Q30238693-AB1BD261-76FD-47D1-94E7-CC9FFEC33C17Q30657233-DB84BD06-4E9F-4058-BBAF-1CA3FC271C73Q30916013-7FF75516-6690-4C29-801D-BD189AE16EBEQ34052920-0B6D449C-D1CF-49DD-B3D5-F4133F70987BQ34346730-8D6D6FE8-205B-4C3B-BA65-072AC7AA7E4EQ34558670-3D61A10F-C903-4899-8508-BCD75B6E1E30Q35677257-3B429B85-04FD-4A2B-A075-057F992AC6C0Q36053801-A594739E-4EAD-44C3-8EDE-62036BFA517EQ36113189-BA891496-4EAA-47EA-B9A8-3E267BD9A393Q36240957-687E147D-5360-436A-B934-BB524A9E2973Q36378134-5F22A5B8-6B43-4362-BA06-420F6E1B3200Q36387812-046AB809-D046-4295-8D5F-0CF28E92F89EQ36446812-46CEAF75-F802-4F6C-B315-F2A096963EE0Q37149909-F182E56D-10DD-4A5A-9357-512587C6B10FQ37415141-E7BC53E1-3A9F-401E-9E74-0109A793A257Q37702165-EB3D1D60-7318-4E40-ADDA-75AC99EE22C0Q38029366-96E8E2DC-D267-4C4A-A493-92B45F74142DQ38068818-7FFD944E-6435-465F-854C-B620F8FD9C42Q38088418-54ABC262-4F12-458E-9906-A61C75703E31Q38240010-EC3055E9-EEF0-4BED-A2B3-74AAEBF3C9BBQ38635551-B0F4DC69-AFCB-4177-BD36-B5E9B88E43B5Q38702196-5C6370D4-FE11-4923-BEA4-29C66D73FAB4Q38953705-99974594-D2BD-459B-9188-919670BC34C7Q39229837-DFDD7E19-957C-4E38-A87F-F6AFA88F21D5Q41135966-53B51BE1-8454-4186-96FE-A2FCE4CBAFC9Q41885084-F4685260-76CD-43C5-93E8-B337B89CC65DQ44574457-12FC662F-C048-4DAC-A9E4-0D6FC8B08217Q46522600-4033ACF4-9699-4E3E-AC08-5053F7F68428
P2860
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Segmental chromosomal alterati ...... a SIOPEN collaborative study).
@ast
Segmental chromosomal alterati ...... a SIOPEN collaborative study).
@en
type
label
Segmental chromosomal alterati ...... a SIOPEN collaborative study).
@ast
Segmental chromosomal alterati ...... a SIOPEN collaborative study).
@en
prefLabel
Segmental chromosomal alterati ...... a SIOPEN collaborative study).
@ast
Segmental chromosomal alterati ...... a SIOPEN collaborative study).
@en
P2093
P2860
P50
P356
P1476
Segmental chromosomal alterati ...... a SIOPEN collaborative study).
@en
P2093
A de Lacerda
A di Cataldo
B Brichard
B de Bernardi
D A Tweddle
E Villamon
P2860
P2888
P304
P356
10.1038/BJC.2011.472
P407
P577
2011-11-10T00:00:00Z
P5875
P6179
1018250199